introduction cardiovascular disease cvd including atherosclerosis heart failure cerebrovascular disease peripheral vascular disease cardiac abnormality leading cause death worldwide prevalence fatality rate increasing every year approximately 655,000 american die result cardiovascular disease resulting massive economic burden aspirin nonsteroidal anti-inflammatory drug shown inhibit formation various inflammatory mediator adhesion molecule resulting anti-atherosclerosis aspirin reduces risk major vascular event used primary cvd prevention result role aspirin prevention treatment cvd widely acknowledged medical community hmg-coa reductase enzyme starting point cholesterol synthesis statin compete enzyme thus impede beginning cholesterol production statin class lipid-lowering drug substantial impact decreasing lipid delaying plaque development thus lowering morbidity death individual atherosclerotic cvd statin therapy shown reduce risk cardiovascular event used primary prevention cvd therefore prevention primary cvd combination statin aspirin beneficial aspirin alone however unclear combination aspirin statin provides greatest protection cardiovascular event therefore used data national health nutrition examination survey nhanes database investigate type statin combined aspirin best effect cvd prevention material method study population nhanes database complex survey combine interview physical examination obtain nationally representative sample civilian noninstitutionalized united state u.s. population http study analyzed nhanes data four 2-year cycle 2011–2018 participant missing cvd information aspirin statin medication questionnaire 16,090 16,449 respectively excluded finally total participant took part study current study relied existing data nhanes database involve collection new data ethical approval required national center health statistic institutional review board approved nhanes procedure participant provided written informed consent nhanes website http contains complete information survey design methodology data aspirin statin use use aspirin various statin determined using data standardized nhanes 2011–2018 questionnaire determine use aspirin participant asked following question doctor health care provider advise take low-dose aspirin every day prevent heart attack stroke cancer ever told taking low-dose aspirin every day prevent heart attack stroke cancer using questionnaire binary variable yes created indicate participant current aspirin use term statin use participant asked used medication required prescription previous month said yes asked show investigator medication container product used statin generic name atorvastatin lovastatin pravastatin rosuvastatin simvastatin combination product studied nhanes website http contains detailed information procedure covariates following covariates downloaded nhanes database age sex race/ethnicity family poverty income ratio pir education level marital status history hypertension diabetes mellitus smoker alcohol user body mass index bmi physical activity mean energy intake hemoglobin high-density lipoprotein-cholesterol hdl-c total cholesterol triglyceride blood urea nitrogen bun uric acid serum creatinine scr home interview following data self-reported participant age sex race/ethnicity education level marital status smoking status drinking status mean energy intake sex dichotomized two group male female education categorized five group 9th grade 9–11th grade high school college graduate self-identified race/ethnicity grouped mexican american hispanic non-hispanic white non-hispanic black race marital status categorized three group married separated never married family poverty-to-income defined total family income divided poverty threshold addition data hdl-c bun scr obtained laboratory test frequency aspirin use includes one every day aspirin one every day aspirin detail variable available online http cvd ascertainment primary outcome study cvd defined composite five self-reported outcome congestive heart failure chf coronary heart disease chd angina pectoris heart attack stroke participant recorded cvd she/he answered yes following question doctor health professional ever told congestive heart failure/coronary heart disease/angina pectoris/stroke standardized medical condition questionnaire administered personal interview provides detailed information www.cdc.gov/nchs/nhanes/ primary prevention defined study prevention first occurrence cardiovascular event self-reported chd chf angina/angina pectoris heart attack stroke statistical analysis continuous variable presented mean standard deviation categorical variable frequency percentage furthermore built three model model adjusted age sex model adjusted age sex race educational level marital status family pir smoker alcohol user hypertension bmi model adjusted potential confounding factor listed table multivariable logistic regression model used investigate use aspirin combination various statin primary cvd prevention stratified interaction model used perform subgroup analysis analysis performed version 3.6.4 foundation statistical computing vienna austria spss version 22.0 spss inc. chicago usa empowerstats software http value 0.05 regarded statistically significant table demographic characteristic study participant full size table ethical approval consent participate nhanes participant provided written informed consent national center health statistic obtained institutional review board approval prior data collection nhanes data de-identified publicly available analysis presented exempt irb review result baseline characteristic table show baseline characteristic study participant total people aged 66.45 10.22 year included study according weighted analysis number people included study represents overall u.s. population 2,468,896 cvd present 27.7 population significant difference baseline characteristic cvd group non-cvd group exception alcohol user bmi association aspirin different statin use total cvd table show result multivariable logistic regression analysis association aspirin different statin use total cvd controlling underlying cofounder odds ratio confidence interval cvd 0.43 0.33 0.57 0.69 0.42 1.13 0.44 0.31 0.62 0.34 0.23 0.50 0.64 0.49 0.84 aspirin different statin combination atorvastatin lovastatin pravastatin rosuvastatin simvastatin table association aspirin alone compared aspirin plus statin risk total cvd full size table association aspirin different statin use individual cvds separate analysis conducted examine relationship aspirin various statin use individual cvds chf chd angina pectoris heart attack stroke finding revealed strong link use aspirin different statin prevalence individual cvds chd chf angina pectoris heart attack individual cvds 0.47 0.27 0.84 0.24 0.15 0.39 0.24 0.13 0.42 0.30 0.19 0.49 0.98 0.54 1.81 fully adjusted model rosuvastatin aspirin combination respectively compared aspirin use alone table table association aspirin alone compared aspirin plus statin risk individual cvd full size table subgroup analysis subgroup analysis carried based age sex hypertension bmi table respect subgroup analysis age sex bmi rosuvastatin combined aspirin shown effective prevention cvd however population without hypertension combination atorvastatin plus aspirin effective preventing cvd furthermore significant difference use different statin aspirin preventing cvd term age hypertension table subgroup analysis association aspirin alone compared aspirin plus statin prevalence total cvd full size table discussion aging population incidence cardiovascular event gradually increasing elderly meanwhile various risk factor unhealthy lifestyle environmental pollution also make incidence cardiovascular event young population gradually increased important way prevent cvd promote healthy lifestyle throughout life besides drug control another important method revealing acc/aha guideline thus great importance focus primary drug prevention cardiovascular event general population commonly used drug cardiovascular system several consensus acknowledged benefit aspirin cvd primary prevention especially prominent function reducing risk nonfatal myocardial infarction stroke meanwhile use aspirin also lead increased incidence bleeding shown large-scale meta-analysis gaziano constructed large randomized multicenter clinical trial discovered based low cvd risk participant cvd event rate much lower expected participant administrated aspirin illustrated benefit aspirin cvd primary prevention statin first choice reducing high blood cholesterol risk factor cvd event mainly due reduction cholesterol biosynthesis taylor summarized people without evidence cvd treated statin showed reduction all-cause mortality major vascular event revascularizations excess adverse event researcher constructed several clinical trial evaluate whether combination use aspirin statin could beneficial patient athyros found comparing statin aspirin used alone combination usage aspirin statin significantly reduced cvd event dyslipidaemic patient korean national cohort study evaluating efficacy aspirin statin primary prevention cardiovascular mortality showed combination use aspirin statin could benefit participant statin therapy improve peripheral atherosclerosis reverse atherosclerotic plaque however rare research focused choice statin combination use aspirin cvd primary prevention based large-scale population integrated nhanes database reported combination aspirin rosuvastatin could remarkably reduce incidence total individual cvds comparing combination use aspirin kind statin revealing advantage rosuvastatin rosuvastatin latest potent statin currently market compared statin rosuvastatin fully synthetic statin act interfering endogenous synthesis cholesterol competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme primary prevention population statin reduced risk all-cause cvd mortality harm risk also increased different statin type different benefit-harm profile drug-level network meta-analysis showed atorvastatin rosuvastatin reduced cvd event effectively liping also found risk adverse reaction increased rosuvastatin compared atorvastatin addition intermediate-risk ethnically diverse population without cvd rosuvastatin per day significantly decreased cardiovascular event compared placebo compared statin rosuvastatin shown reduce ldl cholesterol effectively statin best efficacy reducing total cholesterol low-density lipoprotein cholesterol ldl-c also increase hdl-c atorvastatin east asian patient hypercholesterolemia zhang team revealed rosuvastatin effective atorvastatin however perez-calahorra found difference ascvd recurrence high dos rosuvastatin atorvastatin strength limitation strength study included relatively large sample size investigate use aspirin conjunction various statin cvd prevention despite fact research found combining aspirin statin advantageous cardiovascular system general population important option primary prevention still lifestyle modification specific group classification nhanes offer explored whether individual low moderate high cvd risk better provide drug usage evidence evaluate advantage adverse effect aspirin different stain also considered conclusion result demonstrate combination use aspirin statin effective using aspirin alone cvd prevention based large-scale u.s. general population moreover rosuvastatin showed remarkable effect total individual cvds prevention comparing statin combining use aspirin